Similar articles for PMID: 29663157

Year	Number of Results
1940	1
1995	1
1996	1
1997	1
1998	2
1999	2
2000	7
2001	3
2002	2
2003	1
2005	4
2006	1
2007	3
2008	1
2010	4
2011	1
2012	4
2013	3
2014	4
2015	12
2016	8
2017	10
2018	10
2019	6
2020	1
2021	2
2022	2
2023	1
2024	0

1

Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis.

Lim CC, Mok IYJ, Choo JCJ. Lim CC, et al. Clin Rheumatol. 2018 Jul;37(7):2011-2012. doi: 10.1007/s10067-018-4101-7. Epub 2018 Apr 16. Clin Rheumatol. 2018. PMID: 29663157

2

Risk-stratified approach to anti-viral prophylaxis against cytomegalovirus disease in glomerulonephritis and renal vasculitis treated with potent immunosuppressants.

Lim CC, Tan BH, Tung YT, Huang H, Hao Y, Mok IYJ, Lee PH, Choo JCJ. Lim CC, et al. Infect Dis (Lond). 2019 Oct;51(10):745-752. doi: 10.1080/23744235.2019.1648855. Epub 2019 Aug 13. Infect Dis (Lond). 2019. PMID: 31407631

3

CMV disease complicating induction immunosuppressive treatment for ANCA-associated vasculitis.

Tollitt J, O'Riordan E, Poulikakos D. Tollitt J, et al. BMJ Case Rep. 2016 Feb 23;2016:bcr2015214018. doi: 10.1136/bcr-2015-214018. BMJ Case Rep. 2016. PMID: 26907821 Free PMC article.

4

Cytomegalovirus-associated supraglottic mass in a patient on immunosuppressive therapy.

Anavi KR, Nel C, Savage-Reid MJ, Adzatia KE, Nel JS. Anavi KR, et al. S Afr Med J. 2021 Jun 30;111(7):623-626. doi: 10.7196/SAMJ.2021.v111i7.15614. S Afr Med J. 2021. PMID: 34382544

5

The complications of vasculitis and its treatment.

King C, Harper L, Little M. King C, et al. Best Pract Res Clin Rheumatol. 2018 Feb;32(1):125-136. doi: 10.1016/j.berh.2018.07.009. Epub 2018 Aug 28. Best Pract Res Clin Rheumatol. 2018. PMID: 30526892 Review.

6

Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Morishita M, Sada KE, Matsumoto Y, Hayashi K, Asano Y, Hiramatsu Asano S, Ohashi K, Miyawaki Y, Katsuyama E, Watanabe H, Kawabata T, Wada J. Morishita M, et al. PLoS One. 2019 Jul 10;14(7):e0218705. doi: 10.1371/journal.pone.0218705. eCollection 2019. PLoS One. 2019. PMID: 31291263 Free PMC article.

7

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.

Strippoli GF, Hodson EM, Jones CJ, Craig JC. Strippoli GF, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005133. doi: 10.1002/14651858.CD005133.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437521 Updated. Review.

8

Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.

Reischig T. Reischig T. Expert Rev Anti Infect Ther. 2012 Jan;10(1):51-61. doi: 10.1586/eri.11.156. Expert Rev Anti Infect Ther. 2012. PMID: 22149614 Review.

9

Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review.

Leong A, Fong W. Leong A, et al. Int J Rheum Dis. 2022 Dec;25(12):1357-1367. doi: 10.1111/1756-185X.14444. Epub 2022 Sep 22. Int J Rheum Dis. 2022. PMID: 36135777 Review.

10

Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.

Bueno J, Ramil C, Green M. Bueno J, et al. Paediatr Drugs. 2002;4(5):279-90. doi: 10.2165/00128072-200204050-00001. Paediatr Drugs. 2002. PMID: 11994033 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year